In a recent Nature article, Middleton et al. report the National Lung Matrix trial results where patients with previously treated non-small cell lung cancer (NSCLC) are assigned to personalized therapy based on the results of a 28-gene next-generation sequencing panel test.
from Cancer Cell https://ift.tt/2EJTuva
from Cancer Cell https://ift.tt/2EJTuva